Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its affiliate VGX International Inc. has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for Inovio’s SynCon™ preventive DNA vaccine (VGX-3400) targeting H5N1 avian influenza.
SAN DIEGO—-Inovio Biomedical Corporation , a leader in DNA vaccine design, development and delivery, announced today that its affiliate VGX International Inc. has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for Inovio’s SynCon™ preventive DNA vaccine targeting H5N1 avian influenza.
Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.
Continued here:
Novavax Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy … (BioresearchOnline)
Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.
See original here:
NOVAVAX Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy … (PharmaceuticalOnline)
ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.
Read the rest here:
NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy … (redOrbit)
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has filed the application with China’s State Food and Drug Administration (SFDA) to commence a human clinical trial for its vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD). This is the first clinical trial application for HFMD vaccine submitted …
Original post:
SVA submits the first clinical trial application for HFMD vaccine in China (News-Medical-Net)
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2 , and H5N1 influenza vaccine candidates achieved …
Go here to see the original:
new research findings two: The newest of the deadly vaccines …
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2 , and H5N1 influenza vaccine candidates achieved …
Link:
H1N1, H2N2, H3N2, and H5N1 Combo DNA Influenza Vaccine Ready To Roll.
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2 , and H5N1 influenza vaccine candidates achieved …
See the article here:
H1N1, H2N2, H3N2, and H5N1 Combo DNA Influenza Vaccine Ready …
… announced today that a combination of itssynthetic consensus H1N1, H2N2, H3N2 , and H5N1 influenza vaccinecandidates achieved protective antibody responses against severaldifferent influenza sub-types and strains in ferrets. …
The rest is here:
Bird Flu Monitor: Prevalence of Antibodies against Avian Influenza …